These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3917353)

  • 1. Renal complications of mitomycin C therapy with special reference to the total dose.
    Valavaara R; Nordman E
    Cancer; 1985 Jan; 55(1):47-50. PubMed ID: 3917353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal toxicity of mitomycin-C.
    Ravikumar TS; Sibley R; Reed K; Grage TB
    Am J Clin Oncol; 1984 Jun; 7(3):279-85. PubMed ID: 6428215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary hypertension, hemolytic anemia, and renal failure. A mitomycin-associated syndrome.
    McCarthy JT; Staats BA
    Chest; 1986 Apr; 89(4):608-11. PubMed ID: 3082608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy with doxorubicin and mitomycin C in non-small cell bronchogenic carcinoma. Severe pulmonary toxicity from q 3 weekly mitomycin C.
    Doyle LA; Ihde DC; Carney DN; Bunn PA; Cohen MH; Matthews MJ; Puffenbarger R; Cordes RS; Minna JD
    Am J Clin Oncol; 1984 Dec; 7(6):719-24. PubMed ID: 6442103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mytomycin C nephrotoxicity. 3 new cases and review of the literature].
    Simon P; Hervé JP; Ramée MP; Leroy JP; Ang KS; Leguy P; Vignoud J; Cledes J
    Nephrologie; 1982; 3(4):152-7. PubMed ID: 6818483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitomycin C-induced renal toxicity, a dose-dependent side effect?
    Verwey J; de Vries J; Pinedo HM
    Eur J Cancer Clin Oncol; 1987 Feb; 23(2):195-9. PubMed ID: 3127216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of mitomycin-C in patients with small cell carcinoma of the lung after failure on combination chemotherapy.
    Joss RA; Obrecht JP; Senn HJ; Alberto P; Sauter C; Cavalli F
    Eur J Cancer Clin Oncol; 1984 Dec; 20(12):1477-9. PubMed ID: 6094197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I-II study of continuous 5-day infusion mitomycin-C.
    Yap HY; Valdivieso M; Blumenschein G; Hortobagyi G; Bedikian A
    Am J Clin Oncol; 1983 Feb; 6(1):109-12. PubMed ID: 6404154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silent renal microangiography after mitomycin C therapy.
    Poch E; González-Clemente JM; Torras A; Darnell A; Botey A; Revert L
    Am J Nephrol; 1990; 10(6):514-7. PubMed ID: 2127509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal disease after mitomycin C therapy.
    Hanna WT; Krauss S; Regester RF; Murphy WM
    Cancer; 1981 Dec; 48(12):2583-8. PubMed ID: 6796250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
    Rosell R; Abad-Esteve A; Moreno I; Barnadas A; Carles J; Fernandez C; Ribelles N; Culubret M
    Cancer; 1990 Apr; 65(8):1692-9. PubMed ID: 2156597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microangiopathic hemolytic anemia, a frequent complication of mitomycin therapy in cancer patients.
    Bruntsch U; Groos G; Tigges FJ; Gallmeier WM
    Eur J Cancer Clin Oncol; 1984 Jul; 20(7):905-9. PubMed ID: 6540191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer.
    Cartei G; Cartei F; Cantone A; Causarano D; Genco G; Tobaldin A; Interlandi G; Giraldi T
    J Natl Cancer Inst; 1993 May; 85(10):794-800. PubMed ID: 8387607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Fluorouracil, high-dose folinic acid, and mitomycin C combination chemotherapy in advanced gastrointestinal adenocarcinomas. A pilot study.
    Becouarn Y; Brunet R; Bussières E; Marée D
    Oncology; 1988; 45(4):269-72. PubMed ID: 3133620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy.
    Cantrell JE; Phillips TM; Schein PS
    J Clin Oncol; 1985 May; 3(5):723-34. PubMed ID: 3923162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cis-platinum and mitomycin-C in treatment of recurrent, metastatic, or residual uterine cervical cancer post radiation.
    Senapad S; Neungton S; Usavajindawath C; Vijatrasil S; Thaithanaisawanya V
    J Med Assoc Thai; 1989 Jul; 72(7):382-6. PubMed ID: 2507723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitomycin-C and metronidazole in the treatment of advanced renal-cell carcinoma.
    Stewart DJ; Futter N; Irvine A; Danjoux C; Moors D
    Am J Clin Oncol; 1987 Dec; 10(6):520-2. PubMed ID: 3120573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Three cases of renal failure associated with microangiopathic hemolytic anemia after mitomycin C therapy].
    Hayano K; Fukui H; Otsuka Y; Hattori S
    Nihon Jinzo Gakkai Shi; 1988 Jul; 30(7):835-42. PubMed ID: 3150472
    [No Abstract]   [Full Text] [Related]  

  • 19. [Microangiopathic hemolytic anemia (MAHA) observed after administration of mitomycin C (MMC)].
    Yasunaga C; Komota T; Mimura K; Kinjyo M; Sueishi K; Hirose T
    Gan No Rinsho; 1987 Jun; 33(7):854-60. PubMed ID: 3112442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Microangiopathic haemolytic anaemia as a complication of mitomycin C treatment (author's transl)].
    Tigges FJ; Bruntsch U; Groos G; Gallmeier WM
    Dtsch Med Wochenschr; 1982 Jan; 107(4):142-5. PubMed ID: 7056168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.